Skip to main content
TipRanks
Go Ultimate75% OFF

Telo Genomics Corp (TELO) AI Stock Analysis

21 Followers
TSE:TELO

Telo Genomics Corp

(TSXV:TELO)

Select Model
Rating:40Underperform
Price Target:CAD 0.04â–¼(-4.44% Downside)
Action:downgraded
Date:10/31/26

Telo Genomics exhibits severe fundamental weakness driven by structural insolvency, persistent cash burn, and zero revenue generation. While technical indicators suggest the stock is heavily oversold and maintaining some long-term moving average support, the overwhelming lack of profitability and high reliance on external financing present critical viability risks.

Positive Factors
Improving Cash BurnThe reduced operating cash burn indicates some progress in controlling cash consumption, even before revenue is established. If sustained, this improvement could extend the company’s funding runway and support continued development while management works toward commercial traction.
Negative Factors
No Reported RevenueThe absence of reported revenue shows that the business has not yet demonstrated commercial traction or a recurring sales engine. This leaves future growth dependent on converting its diagnostic platform into paying clinical or research customers over the coming periods.

Telo Genomics Corp (TELO) vs. iShares MSCI Canada ETF (EWC)

-30%-20%-10%0%10%20%30%40%TSE:TELO-10.00%EWC+16.25%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 5.02M
Dividend Yield
―
Average Volume (3M)
94.79K
Price to Earnings (P/E)
-2.2
Beta (1Y)
1.18
Revenue Growth
―
EPS Growth
25.57%
Country
Canada
Employees
8
Sector
General
Sector Strength
55
Industry
Medical - Diagnostics & Research

Telo Genomics Corp Business Overview & Revenue Model

Company Description

Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health con...

Telo Genomics Corp Financial Statement Overview

Summary

Financials reflect extreme distress with zero revenue, negative stockholders' equity, and persistent cash burn. The company lacks organic financial stability, offset only slightly by a minor recent reduction in operating losses.

Income Statement

5Very Negative

Balance Sheet

8Very Negative

Cash Flow

5Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Sep 2025Sep 2024Jun 2022Sep 2020
Income Statement
Total Revenue000000
Gross Profit-86.56K-86.56K-14.45K-39.54K-33.11K-62.23K
EBITDA-2.10M-2.10M-2.69M-2.67M-2.78M-1.01M
Net Income-2.31M-2.31M-2.72M-2.71M-2.82M-1.07M
Balance Sheet
Total Assets599.90K599.90K911.30K965.64K2.93M3.84M
Cash, Cash Equivalents and Short-Term Investments338.32K338.32K789.29K796.02K2.67M3.64M
Total Debt1.44M1.44M0032.50K40.00K
Total Liabilities2.18M2.18M396.32K375.59K312.87K153.66K
Stockholders Equity-1.58M-1.58M514.98K590.06K2.61M3.69M
Cash Flow
Free Cash Flow-1.61M-1.61M-2.33M-2.46M-2.70M-1.11M
Operating Cash Flow-1.59M-1.59M-2.33M-2.46M-2.63M-1.10M
Investing Cash Flow-18.75K-18.75K-3,250-5,115-69.06K-9,310
Financing Cash Flow1.16M1.16M2.33M587.05K2.68M3.83M

Telo Genomics Corp Technical Analysis

Technical Analysis SentimentPositive
Last Price0.04

Price Trends

50DMA0.05Positive
100DMA0.04Positive
200DMA0.05Positive

Market Momentum

MACD-0.00Positive
RSI54.96Neutral
STOCH-16.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELO, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.05, indicating a bullish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 54.96 is Neutral, neither overbought nor oversold. The STOCH value of -16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TELO.

Telo Genomics Corp Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TSE:TELO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TSE:BUXTSE:BUX41NeutralCAD 44.72M-31.11-250.77%―-82.05%23.73%
TSE:KNETSE:KNE40UnderperformCAD 6.15M-2.05273.53%―――
TSE:SONATSE:SONA40UnderperformCAD 30.70M-11.68448.05%――24.65%
TSE:TELOTSE:TELO40UnderperformCAD 5.01M-2.17295.03%――25.57%
TSE:AVCRTSE:AVCR38UnderperformCAD 5.69M-2.27-241.33%―-93.73%-25.53%

* General Sector Average

Performance Comparison

-50%0%50%TSE:TELOTSE:BUXTSE:SZLS.HTSE:KNETSE:SONATSE:AVCRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:TELO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:TELOTelo Genomics0.04-0.01-25.00%
TSE:BUXBioMark Diagnostics0.420.0718.31%
TSE:SZLS.HStagezero Life Sciences0.040.000.00%
TSE:KNEKane Biotech0.03-0.01-25.00%
TSE:SONASona Nanotech, Inc0.26-0.29-52.78%
TSE:AVCRAvricore Health 0.04-0.02-25.86%

Telo Genomics Corp Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Telo Genomics Secures $250,000 Term Loan for Operations

Positive
Nov 6, 2026

Telo Genomics is a biotechnology company developing diagnostic and prognostic tests based on three-dimensional telomere analysis. Its platform targets liquid biopsy applications in oncology and neurological diseases, serving clinicians, pathologists,...

Business Operations and StrategyProduct-Related Announcements

Telo Genomics Expands Global Studies to Validate Blood-Based Myeloma MRD Test

Positive
Oct 29, 2026

Telo Genomics Corp. is a Vancouver-based diagnostics company developing diagnostic and prognostic tests that use three-dimensional analysis of telomeres, the ends of chromosomes. Its flagship liquid-biopsy assay, TELO-MRD, targets measurable residual...

Business Operations and Strategy

Telo Genomics’ Blood-Based TELO-MRD Shows Strong MRD Detection in Multiple Myeloma Comparisons

Positive
Sep 29, 2026

Telo Genomics has reported new clinical research results from its TELO-MRD program in multiple myeloma, comparing blood-based TELO enumeration of circulating plasma cells with bone-marrow Adaptive clonoSEQ next-generation sequencing. The company’s li...

Business Operations and StrategyProduct-Related Announcements

Telo Genomics’ Blood-Based Myeloma Assay Outperforms Bone-Marrow MRD Test in Study

Positive
Sep 16, 2026

Telo Genomics reported clinical research results showing that its TeloView-based TELO-MRD blood assay detected residual multiple myeloma cells in a substantially higher proportion of matched samples than standard bone-marrow EuroFlow next-generation...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026